Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.40
Bid: 9.30
Ask: 9.50
Change: 0.00 (0.00%)
Spread: 0.20 (2.151%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.40
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

e-Therapeutics' Impact is rated World Class

19 Dec 2014 07:00

RNS Number : 2500A
e-Therapeutics plc
19 December 2014
 

 

e-Therapeutics plc ("e-Therapeutics" or the "Company")

 

e-Therapeutics' Impact is rated World Class and helps its "home" Computing Science Department to Number 1 in UK National Research and Impact Assessment

 

Oxford and Newcastle, UK, 18 December 2014 - The impact of e-Therapeutics plc (AIM: ETX) drug discovery activities has been rated World Class by the UK's National Research and Impact Assessment exercise. 

 

The impact case study on e-Therapeutics was submitted by Newcastle University's Computing Science department, and this rating helped the Department to the number 1 position in the UK for the impact of its research. 

 

The Research Excellence Framework (REF) is the five-yearly assessment of the quality of research and impact in all departments of all universities in the UK. The level of impact is an important aspect of the assessment of the quality of research in UK science departments. The REF highlighted the wide-ranging and significant benefits that UK research brings to the economy and society. For more information, please see: www.ref.ac.uk.

 

Malcolm Young, CEO of e-Therapeutics, and a Visiting Professor at the University, said: 

 

"We are proud of our association with Newcastle University. We are delighted that the quality of its computing science, and through e-Therapeutics, its beneficial impact for society, has been recognised by achieving the top spot in the REF."

 

-Ends-

 

Contacts:

 

e-Therapeutics plc

Malcolm Young / Steve Medlicott

Tel: +44 (0) 7733 263 513

www.etherapeutics.co.uk 

 

N+1 Singer

Aubrey Powell/ Jen Boorer

Tel: +44 (0) 20 7496 3155

www.n1singer.com

 

Instinctif Partners

Melanie Toyne Sewell / Emma Barlow

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

 

 

About e-Therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUWVARSRAUAUA
Date   Source Headline
21st Oct 20209:06 amRNSIssue of Equity
12th Oct 20203:15 pmRNSHolding(s) in Company
12th Oct 20207:00 amRNSAppointment of Ali Mortazavi as CEO
12th Oct 20207:00 amRNSInterim Results for six months ended 31 July 2020
5th Oct 202012:07 pmRNSNotice of Interim Results
28th Sep 20207:00 amRNSExpansion of Scientific Advisory Board
28th Jul 20205:46 pmRNSHolding(s) in Company
23rd Jul 202010:03 amRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20207:01 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSDirector/PDMR Shareholding
15th Jul 20207:00 amRNSDirector/PDMR Shareholding
14th Jul 20204:49 pmRNSExercise of Broker Option and Total Fundraise
9th Jul 20204:47 pmRNSExercise of Broker Option
8th Jul 20204:41 pmRNSSecond Price Monitoring Extn
8th Jul 20204:36 pmRNSPrice Monitoring Extension
8th Jul 20202:05 pmRNSSecond Price Monitoring Extn
8th Jul 20202:00 pmRNSPrice Monitoring Extension
8th Jul 20207:00 amRNSResult of Retail Offer
7th Jul 20205:46 pmRNSRetail Offer
7th Jul 20205:42 pmRNSFundraise of up to £12.4 million
22nd Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20207:00 amRNSCollaboration with Galapagos
3rd Jun 20205:52 pmRNSHolding(s) in Company
2nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:36 pmRNSPrice Monitoring Extension
2nd Jun 20202:30 pmRNSResults of 2020 Annual General Meeting
28th May 20207:04 amRNSExpansion into RNAi and creation of SAB
18th May 20204:41 pmRNSSecond Price Monitoring Extn
18th May 20204:37 pmRNSPrice Monitoring Extension
18th May 202011:05 amRNSSecond Price Monitoring Extn
18th May 202011:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSExperimental testing initiated with WuXi AppTec
15th May 20205:17 pmRNSAnnual General Meeting – Change of Arrangement
15th May 20203:12 pmRNSe-therapeutics to present at Shares Evening
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 202011:05 amRNSSecond Price Monitoring Extn
16th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSAppointment of Chief Business Officer
23rd Mar 20207:00 amRNSAnti-viral drug discovery initiative
17th Mar 20207:00 amRNSResults for the year ended 31 January 2020
11th Mar 20201:30 pmRNSNotification of Full Year Results Date
20th Feb 20206:09 pmRNSHolding(s) in Company
18th Feb 202012:02 pmRNSHolding(s) in Company
11th Feb 202010:00 amRNSDirector/PDMR Shareholding
11th Feb 20207:00 amRNSBoard Changes and Placing
13th Jan 202012:58 pmRNSCorrection - Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.